Yes. Vyvanse shows up on a standard amphetamine drug test, and it is supposed to. Vyvanse is the brand name for lisdexamfetamine, a prodrug that the body converts into dextroamphetamine after it is swallowed. Once that conversion happens, the compound circulating in blood and appearing in urine or saliva is chemically amphetamine, the same analyte that immunoassay panels are built to catch. This is not a lab glitch and it is not a false positive in the way that some over the counter medications can trigger one. It is the drug working exactly as designed, showing up on the amphetamine line of a drug test panel.
That distinction matters for anyone managing a workplace testing program or holding a legitimate prescription. Understanding why the result reads the way it does, and how review of that result actually works, avoids confusion for everyone involved.
What Vyvanse actually is
According to the FDA approved prescribing information on DailyMed, the National Library of Medicine's repository for official drug labeling, "VYVANSE contains lisdexamfetamine, a prodrug of amphetamine, a Schedule II controlled substance." Vyvanse is approved for attention deficit hyperactivity disorder in adults and children six and older, and for moderate to severe binge eating disorder in adults.
A prodrug is inactive until the body converts it into the active compound. Lisdexamfetamine itself has almost no stimulant effect. After oral administration, red blood cells hydrolyze it into dextroamphetamine and l-lysine. The label notes that lisdexamfetamine's own plasma half-life typically averaged less than one hour, and that it becomes non-quantifiable in plasma within about eight hours, while the dextroamphetamine it produces has a longer elimination half-life, approximately 10 to 11.3 hours in healthy adults. In plain terms, the parent compound disappears fast, but the amphetamine it converts into sticks around and is what a drug test panel actually detects.
Which drug test panels catch it
Amphetamine (AMP) is one of the analytes covered on nearly every standard multi panel test, including the federal five panel built around the drugs specified in the mandatory guidelines for federal workplace testing programs maintained by the Substance Abuse and Mental Health Services Administration (SAMHSA). Whether the sample is urine, oral fluid, or hair, an AMP immunoassay screen is designed to react to amphetamine class compounds, and dextroamphetamine from Vyvanse falls squarely into that class.
Extended panels that separate amphetamine (AMP) from methamphetamine (mAMP) as distinct reported analytes will register a Vyvanse related result on the AMP line, not the mAMP line, since lisdexamfetamine converts to dextroamphetamine and not to methamphetamine. A closer look at how those two analytes are distinguished on a lab report is covered in Amphetamine vs Methamphetamine Drug Test: How AMP and mAMP Panels Work.
| Panel type | Analyte line involved | Detects Vyvanse (lisdexamfetamine)? |
|---|---|---|
| Standard multi panel (AMP included) | Amphetamines (AMP) | Yes, reads as amphetamine |
| Extended panel with separate AMP and mAMP | AMP and mAMP reported separately | Yes, reads on the AMP line, not the mAMP line |
| MDMA specific screen | MDMA/MDA | No, dextroamphetamine is not MDMA |
| Panel without an amphetamine analyte | Not applicable | No, the panel is not designed to detect it |
Approximate detection windows
Detection time depends on dose, how long someone has been taking the medication, individual metabolism, hydration, kidney function, and the cutoff concentration the specific test uses. There is no single number that applies to every person, and no source, including this one, can promise an exact detection time for any individual. With that caveat, general ranges commonly discussed for amphetamine class stimulants, grounded in the elimination half-life data on the Vyvanse label, look roughly like this.
| Specimen type | General approximate range | Notes |
|---|---|---|
| Oral fluid (saliva) | Roughly 1 to 2 days after the last dose | Reflects more recent use; timing of collection relative to dosing matters |
| Urine | Roughly 1 to 3 days after the last dose | Most common specimen for workplace and DOT testing |
| Hair | Up to about 90 days | Reflects a longer usage pattern, not a single recent dose |
These ranges are general information only, not a guarantee for any specific person or test. A daily, prescribed dose behaves differently than a single dose, and individual physiology can push actual detection outside a typical range in either direction.
Why this is a true positive, not a false positive
A false positive happens when a test reacts to something that is not actually the targeted drug, such as certain antihistamines or other medications cross reacting on a screening immunoassay. Vyvanse is different. Once metabolized, the substance present in the specimen is genuinely amphetamine. The screen and, if confirmed, the laboratory grade confirmation test using gas chromatography or liquid chromatography mass spectrometry are both detecting a real amphetamine metabolite, not reacting to a look alike compound. The result is accurate. What determines whether that accurate result becomes a reportable positive is the review process that follows, not the chemistry of the test itself.
How Medical Review Officer review handles it
For DOT regulated testing, and for many non-regulated employer programs that follow the same model, a laboratory confirmed non-negative result does not go straight to the employer. It goes to a Medical Review Officer (MRO), a licensed physician trained to review results and interview the employee before anything is reported. Under 49 CFR §40.137, the federal regulation covering how an MRO verifies results involving amphetamines and several other drug classes, the rule is direct. As the eCFR text of 49 CFR Part 40, §40.137 states, the MRO "must verify a confirmed positive test result for marijuana, cocaine, amphetamines, semi-synthetic opioids...and/or PCP unless the employee presents a legitimate medical explanation for the presence of the drug(s)/metabolite(s) in his or her system," and further, "in determining whether an employee's legally valid prescription consistent with the Controlled Substances Act...constitutes a legitimate medical explanation, you must not question whether the prescribing physician should have prescribed the substance." The same section states that if the MRO determines a legitimate medical explanation exists, the MRO "must verify the test result as negative."
In practice, this means an employee with a valid, current Vyvanse prescription who is contacted by the MRO and provides that information should have the result verified as negative before it ever reaches the employer's file. The employee carries the burden of presenting that information at the verification interview, and the MRO has discretion to allow a short additional window to produce documentation if there is a reasonable basis to believe it exists. The broader mechanics of this process, including what happens for other amphetamine class prescriptions like Adderall, are covered in Adderall and Drug Tests: Why Amphetamine Positives Happen and How MRO Review Works.
DOT versus non-DOT context
DOT regulated safety sensitive positions, covered under 49 CFR Part 40, require the MRO verification process described above without exception, and the analytes and testing procedures are standardized across the regulated industries FMCSA, FAA, FRA, FTA, and PHMSA oversee. Non-DOT employer programs are not bound by Part 40 unless they choose to follow it, but many employers voluntarily adopt the same MRO review structure because it is a well established, defensible model. SAMHSA's mandatory guidelines, referenced through its federal workplace testing program materials, set the framework that federal executive branch agencies use and that much of the private sector testing industry has modeled its own programs after. An employer building or reviewing a testing policy that includes amphetamine screening should decide upfront whether MRO review applies and make that expectation clear in its written policy.
What a legitimate prescription holder should expect
Someone taking Vyvanse as prescribed does not need to disclose that fact before providing a specimen. Federal collection procedures do not ask donors to list current medications at the collection site. If the screen comes back non-negative for amphetamines, the next step is a phone call or contact attempt from the MRO, not an automatic report to the employer. At that point, having the prescribing provider's name and being able to confirm the prescription is what the MRO needs to complete review. Nothing about this process requires disclosing a diagnosis, only that a valid, legally obtained prescription accounts for the result.
Employers setting up a testing program that includes amphetamine detection should build their panel selection and collection supplies around confirmed, defensible protocols. American Screening Corporation's workplace drug testing solutions for employers include multi panel cups and dip cards that cover the AMP analyte alongside other commonly screened drug classes, suited to programs that route non-negative results through MRO review.
Frequently asked questions
Is a positive Vyvanse result a false positive?
No, it is not a false positive. Vyvanse is lisdexamfetamine, a prodrug that the body converts to dextroamphetamine after ingestion. Standard amphetamine immunoassay panels are designed to detect that metabolite, so a screen and confirmation test reading amphetamine after Vyvanse use reflects the drug actually working as intended, not a lab error.
Will Vyvanse show up as methamphetamine?
No. Lisdexamfetamine converts to dextroamphetamine, not methamphetamine. Amphetamine (AMP) and methamphetamine (mAMP) are reported as separate analytes on multi panel drug tests, and a Vyvanse related positive should read on the amphetamine line, not the methamphetamine line.
Do I have to tell my employer I take Vyvanse before a drug test?
Federal workplace testing rules do not require employees to disclose medications before a specimen is collected. If a screen comes back non-negative for amphetamines, a Medical Review Officer contacts the employee directly and gives them a chance to explain a legitimate prescription before any result is reported to the employer.
Does a valid Vyvanse prescription get reported to my employer as positive?
Under the federal MRO review process described in 49 CFR Part 40, when an employee has a legitimate prescription for a substance that produced the confirmed result, the MRO verifies the test as negative rather than reporting it as positive to the employer.
How long does Vyvanse stay detectable in a urine test?
Detection windows vary with dose, frequency of use, metabolism, hydration, and the specific test's cutoff level, so no single number applies to everyone. As a general range, amphetamine metabolites from lisdexamfetamine are often discussed as detectable in urine for roughly one to three days after the last dose, though this is not a guarantee for any individual.
This article is general information, not legal or medical advice. Detection windows and MRO review outcomes vary by individual, employer policy, and applicable state law, and anyone with questions about a specific prescription or test result should speak with a qualified physician, MRO, or attorney.
